Overview

Country(s): Austria, Belgium, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Norway, Poland, Romania, Spain, Sweden, Turkey,

Deadline: Pre-proposal deadline: March 2019 (TBC - Call opening early January 2019)

PROGRAMME SUMMARY

ERA PerMed is an ERA-Net Cofund, supported by 32 partners of 23 countries and co-funded by the European Commission (EC). To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 29 funding organisations have agreed to launch the second Joint Transnational Call for collaborative innovative research projects in Personalised Medicine (PM).

This represents the first of three potential additional calls not co-funded by the EC. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals.

The overall objectives of the ERA PerMed Call are:

  1. to support translational research projects in the field of Personalised Medicine;
  2. to encourage and enable interdisciplinarity, in combining pre-clinical and/or clinical research with computational components and;
  3. to encourage collaboration between academia (research teams from universities, higher education institutions, public research performing institutions), clinical/public health research (research teams from hospital/ public health institutions, healthcare settings and other healthcare organisations) and private partners e.g. SMEs (Small and Medium-size Enterprises).

Proposals must be interdisciplinary and clearly demonstrate the potential impact in PM as well as the added value of transnational collaboration. Only transnational projects will be funded. Each consortium submitting a proposal must involve at least three partners eligible for funding coming from three different countries whose funding organisations participate in the Call.

VIEW AIMS & SCOPE OF THE CALL

Aims of the Call

With its second transnational call, ERA PerMed will foster research and innovation activities building close linkages between basic biomedical research, clinical research, bioinformatics, epidemiology, socio-economic research, as well as research on the integration of PM into clinical practice and on ethical, legal and social implications.

The overarching goal is to improve disease management, with better patient stratification, diagnostics and treatment protocols, and disease prevention. Proposals submitted under this call are expected to demonstrate the applicability of project outcomes into clinical practice as well as to describe the impact on the health care systems. Proposals are expected to include research on ethical, legal and socio-economic implications, including health economics and regulation, and/or research on optimisation of health care systems.

The overall objectives of the ERA PerMed call are

(i) to support translational research projects in the field of Personalised Medicine;

(ii) to encourage and enable interdisciplinary collaborations towards implementation of PM, in combining pre-clinical and/or clinical research with computational components and research on relevant ethical, legal and social aspects (ELSA) and/or research on the optimisation of the health care systems;

(iii) to encourage collaboration between academia (research teams from universities, higher education institutions, public research performing institutions), clinical/public health research (research teams from hospital/ public health institutions, healthcare settings and other healthcare organisations) and private partners e.g. SMEs[1] (Small and Medium-size Enterprises).

[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

Scope of the Call

Proposals must be interdisciplinary and clearly demonstrate the potential impact in PM as well as the added value of transnational collaboration.
The JTC2019 of ERA PerMed will comprise three Research Areas:

Each project proposal MUST address at least one module of Research Area 3 and at least one module of Research Area 1 or 2. The coherent integration and combination of the different Research Areas and Modules in the proposals will be part of the evaluation process.

VIEW GENERAL (ELIGIBILITY) CONDITIONS FOR APPLICATION

Joint research proposals may be submitted by applicants belonging to one the following categories (A, B and/or C), if eligible according to relevant regional/national funding organisations regulations for research funding:

  1. Academia (research teams working in universities, other higher education institutions) or research institutes;
  2. Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;
  3. (Industry) Private partners, e.g. SMEs[1] (small and medium-size enterprises).

Please note: Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual ERA PerMed funding organisation respective of the region/country from which applicants have applied. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations. Applicants are strongly advised to contact their regional/national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below “Contact details of participating members”).

Only transnational projects will be funded. Each consortium submitting a proposal must involve at least three partners eligible for funding coming from three different countries whose funding organisations participate to the call (see list below). All three legal entities must be independent from each other. The maximum number of partners per pre-proposal is six though not more than 2 partners from the same country participating in the call will be accepted in one project consortium (including those partners with own funding).

Research groups not eligible for funding (e.g. from non-funding countries or not fundable according to regional/national regulations of the participating funding organisation) may participate in transnational projects if they are able to secure their own funding. They are considered as full partners and have to be integrated in the pre- and full-proposal templates as such. Maximum one partner with own funding is allowed in consortia with at least 3 partners that are eligible for funding. The coordinator must be eligible to be funded by the participating funding organisations to this call.

At the full-proposal stage, a consortium might be increased up to seven partners in total only by inclusion of a partner coming from an underrepresented country. A list of underrepresented countries will be provided to coordinators invited for full-proposals submission.

[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

If you are looking for potential partners, please have a look at the ICPerMed Partnering Tool

View full Call text on ERA PER MED website

FUNDING SPECIFICS

The FNR supports this Call with 300,000 EUR

APPLICATION INFORMATION

In addition to submitting at ERA PerMed, Luxembourg applicants must also submit the proposal – along with the FNR INTER documents – to the FNR no later than 5 working days after the ERA PerMed deadline(s).

Timeline

The call is planned to be launched in January 2019 with a submission deadline for pre-proposals in March 2019. It is expected, that consortia invited for the full-proposal stage, will need to submit their proposal on 17 June 2019.

This site uses cookies. By continuing to use this site, you agree to the use of cookies for analytics purposes. Find out more in our Privacy Statement